Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Medshine Discovery Inc.

Genentech, Inc.

Guangdong Raynovent Biotech Co., Ltd.

Harbin Zhenbao Pharmaceutical Co., Ltd.

F. Hoffmann-La Roche Ag

Guibai Liang

Guoping Hu

Shuhui Chen

Shilan Liu

Jian Li

Zhengxia Chen

Dahai Wang

Cheng Xie

Joseph P Lyssikatos

Ming Zhang

Peng Li

Anthony A Estrada

Fei Sun

Snahel Patel

Kevin X Chen

Michael Siu

Chaofeng Long

Xiaoxin Chen

Zhuowei Liu

Meibi Dai

Zhifei Fu

Hongjian Wang

Jian Wei Li

Wen Liu

Zhengwei Li

Jiangpeng Liao

Honglin Wang

Yang Zhang

The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2&#x3b8; value, has a diffraction peak at about 11.49&#xb0;, 15.05&#xb0;, 20.14&#xb0;, 21.53&#xb0; or 21.79&#xb0;. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value.

Crystal of tricyclic compound

Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases. 

Syk inhibitor and use method therefor

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II): 

Tyrosine kinase inhibitor and pharmaceutical composition comprising same

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

Vinyl compounds as FGFR and VEGFR inhibitors

Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer. 

Tricyclic compound serving as immunomodulator

The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R, R, R, R, R, R, R, Rand Rhave the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.

Substituted pyrazoles and uses thereof

Growing community of inventors

Shanghai, China

Guibai Liang